# Evopoint Biosciences

Source: https://onco.cc/companies/evopoint-biosciences/  
OnCo record `evopoint-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Evopoint Biosciences is a China-based biotechnology company running 6 late-stage cancer trials of XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma and prostate cancer.

## Summary

Evopoint Biosciences, based in Suzhou, China, is a biotechnology company. An innovation-focused pharmaceutical company (registered in Chinese as Suzhou Xinnuowei Pharmaceutical Technology Co., Ltd., 苏州信诺维医药科技股份有限公司) developing small-molecule and antibody drugs for precision oncology and multi-drug resistant bacterial infections, using in-house small molecule, complex antibody (eMAB) and targeted protein degradation (eGLUE) platforms. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma, prostate cancer, hodgkin lymphoma and pancreatic ductal adenocarcinoma. The largest, NCT06799637 (Study of XNW28012 in Subjects With Advanced Solid Tumours Who Failed Standard Treatments), plans to enrol 350 participants. In May 2025 Evopoint licensed XNW27011, a clinical-stage antibody-drug conjugate against CLDN18.2 being tested in gastric, gastro-oesophageal junction and pancreatic cancers, to Astellas for development outside mainland China, Hong Kong, Macau and Taiwan, for USD 130 million upfront, up to USD 70 million in near-term payments and up to USD 1.34 billion in milestones. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Evopoint Biosciences Inc.
- Tags: ctgov-sponsor
- HQ: Suzhou
- Type: biotech
- Website: https://www.evopointbio.com

## Notes

- Freshened 29 October 2026 from the company's Chinese newsroom (Astellas licence, 30 May 2025). The earlier summary gave a garbled Chinese name; it now uses the registered name printed on the company site. No acquisition, listing or renaming found.

## Sources

- Official website: https://www.evopointbio.com
- Evopoint: exclusive licence of XNW27011 to Astellas (30 May 2025, Chinese): https://www.evopointbio.com/news/detail?id=190
- ClinicalTrials.gov: trials led by Evopoint Biosciences: https://clinicaltrials.gov/search?lead=Evopoint%20Biosciences%20Inc.

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [XNW27011](https://onco.cc/drugs/xnw27011/), [XNW5004](https://onco.cc/drugs/xnw5004/)
- companies: [Astellas](https://onco.cc/companies/astellas/)
- trials: [A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma](https://onco.cc/trials/nct06776952/), [A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment](https://onco.cc/trials/nct06987500/), [Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma](https://onco.cc/trials/nct07730515/), [Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma](https://onco.cc/trials/nct07545603/), [Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments](https://onco.cc/trials/nct06799637/), [Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy](https://onco.cc/trials/nct07823049/), [Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06702995/)

---
JSON: https://onco.cc/api/v1/entities/evopoint-biosciences.json